Results 131 to 140 of about 11,407 (242)

European Network on Optimizing Treatment With Therapeutic Antibodies in Chronic Inflammatory Diseases: Overview, Progress and Perspectives

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Treatment of chronic inflammatory diseases has been revolutionized with the introduction of targeted therapies using therapeutic antibodies. However, a large proportion of patients do not respond to treatment, or they lose response over time.
Konstantin Tachkov, Merita Rumano, James Bluett, Nataša Bogavac‐Stanojević, Erwin Dreesen, Mehmet Itik, Georgios Kararigas, Paweł Kawalec, Marlene Santos, Silje Skrede, Guenka Petrova, Denis Mulleman   +11 more
wiley   +1 more source

Inconsistent standard of care for tuberculosis screening and preventive therapy before initiating systemic psoriasis treatment

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 6, Page 737-744, June 2026.
Summary Background and Objectives Preventive tuberculosis (TB) therapy before initiating MTX or IL‐17/IL‐23/IL‐12/23p40 inhibitors for latent tuberculosis infection (LTBI) is supported by indirect evidence of TB reactivations with TNF inhibitors. However, direct evidence for MTX or IL‐17/IL‐23/IL‐12/23p40 inhibitors is limited.
Christoph Zeyen, Ruben Heuer, Brit Haecker, Tom Schaberg, Alexander Nast   +4 more
wiley   +1 more source

Biosimilars for Psoriasis—Experience from Europe

, 2019
Purpose of Review: Over the last several years, major changes have occurred in Europe regarding the use of biosimilars. Some countries such as Norway, Denmark, and the United Kingdom (UK) have a relatively high market penetration of biosimilars, whereas ...
Torres, Tiago, Boehncke, Wolf-Henning, Skov, Lone, van der Walt, Joelle M., Puig, Lluis, Wu, Jashin J., Zachariae, Claus, Cohen, Arnon D., de Rie, Menno, van de Kerkhof, Peter, Jullien, Denis, Boehncke, Wolf Henning, Strohal, Robert, Young, Helen, Naldi, Luigi, Ryan, Caitriona   +15 more
core   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 6, Page 963-979, June 2026.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault, Emilie Brenaut, Marie‐Emeline Marniquet, Carla Berthault, Lea Canoen, Clarisse Marcombes, Audrey Melin, Raphaël Ouakrat, Julie Charles, Stephane Mouret, Olivier Potie, Laetitia Penso, Laura Pina Vegas, Guillaume Larid, Marine Roux, Colombe Bougeard, Sandy Sylvain, Clara Labonne, Tania Randriamiarana, Da Hee Pitaud, Floriane Etheve, Jeremy Gottlieb, Laurie Gouillon, Marine Chastagner, Emilie Sbidian, Hélène Aubert, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), Hélène Aubert, Marie Masson Regnault, Emilie Brenaut, Emilie Sbidian, Laura Pina Vegas, Laetitia Penso, Jeremy Gottlieb, Marine Roux, Clara Labonne, Tania Randriamiarana, Floriane Etheve, Da Hee Pitaud, Marie‐Emeline Marniquet, Carla Berthault, Clarisse Marcombes, Audrey Melin, Colombe Bougeard, Julie Charles, Olivier Potie, Léa Canoen, Laurie Gouillon, Marine Chastagner, Sandy Sylvain, Guillaume Larid, Raphaël Ouakrat   +51 more
wiley   +1 more source

Biosimilars: presumption of guilt

, 2011
Some chronic systemic diseases, including diabetes mellitus, require the life-long use of biotechnological medical products, of which quality,effectiveness and safety depends the duration and quality of life for patients.Patent protection expiry of many ...
Olga Konstantinovna Vikulova, Marina Vladimirovna Shestakova   +1 more
core   +1 more source

Budget impact analysis of the incorporating of biosimilars in a cancer institute of a philanthropic hospital

Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde
Objective: Global healthcare costs continue to rise annually, and this is a major challenge given the scarce resources and growing prices of innovative drugs. An interesting alternative for reducing costs is the use of biosimilars.
Maria Luísa BRODT-LEMES, Diana Saiara BRUSCATO, Douglas Silva MADRUGA, Joice SMANIOTTO, Julia Roberta SAGGIORATO-LUBIAN, Letícia Tramontina DE-VILLA, Suhélen CAON, Thamyrys Bessa SILVA   +7 more
doaj   +1 more source

Biosimilars and haemophilia [PDF]

Haemophilia, 2018
openaire   +2 more sources

Biosimilars and the extrapolation of indications for inflammatory conditions

, 2017
John RP Tesser,1 Daniel E Furst,2 Ira Jacobs3 1Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 2UCLA Health, Los Angeles, CA, 3Pfizer Inc, New York, NY, USA Abstract: Extrapolation is the approval of a biosimilar for use in an indication ...
Furst DE, Jacobs I, Tesser JRP
core  

Biosimilars: implications for rheumatoid arthritis therapy

, 2017
PURPOSE OF REVIEW: Abbreviated pathways for the approval of biosimilars have been established in the European Union (EU), the United States, and other countries. Biosimilar TNF inhibitors have been available in South Korea and the EU since 2012 and 2013,
Cohen, Stanley, Kay, Jonathan
core   +1 more source

The approaches to the assessment of biosimilarity of biotechnological preparations: quality issues

Регуляторные исследования и экспертиза лекарственных средств, 2018
Due to expiration of patents for most highly demanded biotechnological preparations there is a tendency for the increase in the number of applications for marketing authorisation of biosimilar preparations (biosimilars).
A. N. Mironov, V. A. Merkulov, A. I. Lutseva, O. A. Vaganova, A. A. Bendryshev, T. A. Efremova, E. V. Kirichenko, S. V. Shvets, E. V. Ivanainen   +8 more
doaj